|
nasdaq:vstm
|
2193285
|
Apr 21st, 2024 12:00AM
|
Verastem Oncology
|
13K
|
87.00
|
Open
|
|
Apr 21st, 2024 03:27AM
|
Apr 21st, 2024 03:27AM
|
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com.
Twitter: @VerastemOncolog
|
Open
|
Oncology, pharmaceutical, hematology, biotechnology, cancer, clinical trials, cancer research, blood cancer, CLL, Lymphoma, NHL, and T Cell Lymphoma
|
Open
|
117 Kendrick Street
|
Needham
|
Massachusetts
|
US
|
02494
|
|
Verastem
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vstm
|
2193285
|
Apr 20th, 2024 12:00AM
|
Verastem Oncology
|
13K
|
87.00
|
Open
|
|
Apr 20th, 2024 12:26AM
|
Apr 20th, 2024 05:49PM
|
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com.
Twitter: @VerastemOncolog
|
Open
|
Oncology, pharmaceutical, hematology, biotechnology, cancer, clinical trials, cancer research, blood cancer, CLL, Lymphoma, NHL, and T Cell Lymphoma
|
Open
|
117 Kendrick Street
|
Needham
|
Massachusetts
|
US
|
02494
|
|
Verastem
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vstm
|
2193285
|
Apr 19th, 2024 12:00AM
|
Verastem Oncology
|
13K
|
87.00
|
Open
|
|
Apr 19th, 2024 04:50AM
|
Apr 19th, 2024 04:50AM
|
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com.
Twitter: @VerastemOncolog
|
Open
|
Oncology, pharmaceutical, hematology, biotechnology, cancer, clinical trials, cancer research, blood cancer, CLL, Lymphoma, NHL, and T Cell Lymphoma
|
Open
|
117 Kendrick Street
|
Needham
|
Massachusetts
|
US
|
02494
|
|
Verastem
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vstm
|
2193285
|
Apr 18th, 2024 12:00AM
|
Verastem Oncology
|
13K
|
87.00
|
Open
|
|
Apr 18th, 2024 01:28AM
|
Apr 18th, 2024 07:09PM
|
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com.
Twitter: @VerastemOncolog
|
Open
|
Oncology, pharmaceutical, hematology, biotechnology, cancer, clinical trials, cancer research, blood cancer, CLL, Lymphoma, NHL, and T Cell Lymphoma
|
Open
|
117 Kendrick Street
|
Needham
|
Massachusetts
|
US
|
02494
|
|
Verastem
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vstm
|
2193285
|
Apr 17th, 2024 12:00AM
|
Verastem Oncology
|
13K
|
87.00
|
Open
|
|
Apr 17th, 2024 04:27AM
|
Apr 17th, 2024 03:36PM
|
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com.
Twitter: @VerastemOncolog
|
Open
|
Oncology, pharmaceutical, hematology, biotechnology, cancer, clinical trials, cancer research, blood cancer, CLL, Lymphoma, NHL, and T Cell Lymphoma
|
Open
|
117 Kendrick Street
|
Needham
|
Massachusetts
|
US
|
02494
|
|
Verastem
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vstm
|
2193285
|
Apr 16th, 2024 12:00AM
|
Verastem Oncology
|
13K
|
87.00
|
Open
|
|
Apr 16th, 2024 12:13AM
|
Apr 16th, 2024 11:52AM
|
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com.
Twitter: @VerastemOncolog
|
Open
|
Oncology, pharmaceutical, hematology, biotechnology, cancer, clinical trials, cancer research, blood cancer, CLL, Lymphoma, NHL, and T Cell Lymphoma
|
Open
|
117 Kendrick Street
|
Needham
|
Massachusetts
|
US
|
02494
|
|
Verastem
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vstm
|
2193285
|
Apr 15th, 2024 12:00AM
|
Verastem Oncology
|
13K
|
87.00
|
Open
|
|
Apr 15th, 2024 12:04AM
|
Apr 15th, 2024 05:33PM
|
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com.
Twitter: @VerastemOncolog
|
Open
|
Oncology, pharmaceutical, hematology, biotechnology, cancer, clinical trials, cancer research, blood cancer, CLL, Lymphoma, NHL, and T Cell Lymphoma
|
Open
|
117 Kendrick Street
|
Needham
|
Massachusetts
|
US
|
02494
|
|
Verastem
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vstm
|
2193285
|
Apr 14th, 2024 12:00AM
|
Verastem Oncology
|
13K
|
87.00
|
Open
|
|
Apr 13th, 2024 11:53PM
|
Apr 13th, 2024 11:53PM
|
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com.
Twitter: @VerastemOncolog
|
Open
|
Oncology, pharmaceutical, hematology, biotechnology, cancer, clinical trials, cancer research, blood cancer, CLL, Lymphoma, NHL, and T Cell Lymphoma
|
Open
|
117 Kendrick Street
|
Needham
|
Massachusetts
|
US
|
02494
|
|
Verastem
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vstm
|
2193285
|
Apr 13th, 2024 12:00AM
|
Verastem Oncology
|
13K
|
87.00
|
Open
|
|
Apr 12th, 2024 11:44PM
|
Apr 13th, 2024 12:18PM
|
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com.
Twitter: @VerastemOncolog
|
Open
|
Oncology, pharmaceutical, hematology, biotechnology, cancer, clinical trials, cancer research, blood cancer, CLL, Lymphoma, NHL, and T Cell Lymphoma
|
Open
|
117 Kendrick Street
|
Needham
|
Massachusetts
|
US
|
02494
|
|
Verastem
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vstm
|
2193285
|
Apr 12th, 2024 12:00AM
|
Verastem Oncology
|
13K
|
87.00
|
Open
|
|
Apr 11th, 2024 11:52PM
|
Apr 12th, 2024 09:14AM
|
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com.
Twitter: @VerastemOncolog
|
Open
|
Oncology, pharmaceutical, hematology, biotechnology, cancer, clinical trials, cancer research, blood cancer, CLL, Lymphoma, NHL, and T Cell Lymphoma
|
Open
|
117 Kendrick Street
|
Needham
|
Massachusetts
|
US
|
02494
|
|
Verastem
|
Health Care
|
Pharmaceuticals & Biotechnology
|